tbuckley/cabot-search huggingface dataset:
P266 Outcomes from the introduction of fungal biomarkers to the neutropenic fever pathway in a tertiary haematology department
Authors: R Swayne, D Enoch, S Aliyu, C Crawley, P Krishnamurthy, J Craig, G Follows, B Uttenthal, J Babar, CR Sander
Journal: Thorax (2016)

<h3>Background</h3> Invasive fungal disease (IFD) frequently occurs in febrile neutropenic haemato-oncology patients (NHP). Until 2012 no biomarkers were available for the diagnosis of IFD in our Trust. The neutropenic fever pathway was modified to include serial serum Aspergillus galactomannan (GM), serum Aspergillus PCR (APCR) from national reference laboratory and Bronchoalveolar lavage (BAL) GM and APCR. We compared 299 NHP who were investigated with the original pathway between October 2009 and April 2012 with 307 NHP investigated with the novel pathway between April 2013 and 2015. Primary end point was non-inferiority of novel pathway in terms of 12 month mortality. Secondary outcomes were 30 day mortality, length of treatment, length of stay and confidence of diagnosis based on EORTC/MSG criteria<sup>1</sup> and concordance of the different biomarkers. <h3>Method</h3> Prospective patients (2013–15 cohort) were identified from ward lists. Retrospective patients (2009–12 cohort) were identified from haemato-oncology patients who had had blood cultures and were co-incidentally found to be neutropenic. Medical notes, drug charts, discharge letters and microbiology results were reviewed. <h3>Results</h3> The 2 cohorts were well matched in terms of haemato-oncology diagnosis. The 2009/12 cohort included 561 episodes, with 333 CT chests and 62 bronchospies compared to 508 episodes, 288 CT chests and 86 bronchoscopies in 2013/15 group. 12 month mortality was 42% in 2009/12 versus 34% in 2013/15 cohort. 30 day mortality was 11% for both cohorts. There was no significant difference in length of antifungal treatments, although 24% switched to voriconazole following positive biomarkers. Concordance between serum and BAL GM was 14.8% and APCR was 6.3%. Concordance between serum GM and APCR was 7% and between BAL GM and PCR was 41%. Confidence in diagnosis of IFD increased with the novel pathway See Figure 1. <h3>Conclusion</h3> The introduction of a novel NF pathway was found to be non-inferior in terms of 12 month and 30 day mortality. Although there was increased confidence in the diagnosis of IFD, this did not translate to reduced antifungal treatment, although it did influence switching to voriconazole and secondary chemoprophylaxis. Negative serum GM and PCR did not rule out the diagnosis of IFD and BAL biomarkers were more sensitive than serum ones. <h3>Reference</h3> De Pauw B, <i>et al</i>. <i>Clin Infect Dise</i> 2008;<b>46</b>(12).
Detection of NFKB2 3’end Loos By Quantitative PCR (QPCR) or Detection of NFKB2 Rearrangements Correlate with Bortezomib Response in Multiple Myeloma
Authors: Sampath Ramachandiran, Jean L. Koff, Laurent Garderet, Debra Saxe, Souhila Ikhlef, Nyaya Kelkar, Lee Kaplan, Jean El-Cheikh, Jeffrey M. Switchenko, Susan Sunay, Hanna J. Khoury, Jonathan L. Kaufman, Sagar Lonial, Lawrence H Boise, Jeanne Kowalski, Leon Bernal-Mizrachi
Journal: Blood (2014)
Expansion of Hematopoietic Stem Cells (HSC) from Cord-Blood (CB) Derived Mononuclear Cells (MNC) in Cytokine-Free Environment Using Mesenchymal Cells Spatial Co-Culture System.
Authors: Shai Meretzki, Ora Burger, Osnat Merom-Jacov, Avinoam Kaduri, Jacob M. Rowe, Arnon Nagler
Journal: Blood (2006)
TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1
Authors: Lorenz Jahn, Pleun Hombrink, Renate S. Hagedoorn, Michel G. D. Kester, Dirk M. van der Steen, Tania Rodriguez, Tsvetelina Pentcheva-Hoang, Arnoud H. de Ru, Marjolein P. Schoonakker, Miranda H. Meeuwsen, Marieke Griffioen, Peter A. van Veelen, J. H. Frederik Falkenburg, Mirjam H. M. Heemskerk
Journal: Blood (2017)
P3.02c-081 Complete Blood Count Parameters as Predictive Factors in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab
Authors: Diana Saravia, Bahar Laderian, Wungki Park, Amrita Desai, Fernando Vargas, Roy Elias, Sean Warsch, Raja Mudad, Chukwuemeka Ikpeazu, Adrian Ishkanian, Lisa Balfe, Mohammad Jahanzeb
Journal: Journal of Thoracic Oncology (2017)
The role of GDC-0449, a hedgehog (Hh) pathway inhibitor, on epithelial–mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC) cells lines and its effect on erlotinib and cisplatin.
Authors: M. Maitah, S. Ali, P. LoRusso, F. H. Sarkar, S. M. Gadgeel
Journal: Journal of Clinical Oncology (2011)

10537 Background: EMT, characterized by low E-cadherin, has been proposed as a mechanism for tumor invasion, metastases and resistance to therapeutic agents in many cancers, including NSCLC. The Hh pathway may play a role in inducing EMT. An important ligand of the pathway is Sonic hedgehog (Shh). GDC-0449, an inhibitor of Hh pathway, has shown promising activity in tumors with activated Hh pathway such as basal cell carcinoma. Methods: We assessed the effects of GDC-0449 (20 nM) and down regulation of Shh via siRNA on the EMT features of A549-M (A549 cells exposed to TGF-β1 for 21 days) and of H1299 cell line, which is known to have EMT features. Assessment included the effects on the mRNA levels of E-cadherin and Zeb1 a regulator of EMT, clonogenic growth (colony formation assay), cell motility (wound healing assay) and invasion (matrigel assay) and the influence on the activity of erlotinib and cisplatin in these cell lines (MTT assay). Results: A549-M cells had significantly higher rate of clonogenic growth, cell motility and invasion compared to A549 cells and showed higher resistance to erlotinib and cisplatin. A549-M cells had higher mRNA levels of Shh and Zeb1 and reduced levels of E-cadherin than A549 cells. GDC-0449 reduced clonogenic growth, cell motility and invasion of A549-M and H1299 cells. GDC-0449 reduced the mRNA levels of Gli1 (effector molecule of Hh pathway) and reduced the mRNA levels of Zeb1 and increased the levels of E-cadherin in both cell lines. Pre-treatment with GDC-0449 significantly enhanced the activity of erlotinib (5 and 10 mM) and cisplatin (1mM-10mM) in both cell lines (p < 0.05). Similar results were observed in each of the cell lines with down regulation of Shh by siRNA. Conclusions: GDC-0449, a hedgehog inhibitor can attenuate EMT features in NSCLC cell lines. It can also enhance the activity of erlotinib and cisplatin in NSCLC cell lines that are intrinsically resistant to these agents.
P2.06-022 First-Line Durvalumab plus Tremelimumab vs Platinum-Based Chemotherapy for Advanced/Metastatic NSCLC: Phase 3 NEPTUNE Study
Authors: Tony Mok, Peter Schmid, Gilberto De Castro, Kostas Syrigos, Claudio Martin, Nobuyuki Yamamoto, Osvaldo Arén, Oscar Arrieta, Maya Gottfried, Abdul Rahman Jazieh, Rodryg Ramlau, Constanta Timcheva, Leonardo Trani
Journal: Journal of Thoracic Oncology (2017)
Frequent Pathway Mutations of Splicing Machinery in Myelodysplasia
Authors: Kenichi Yoshida, Masashi Sanada, Yuichi Shiraishi, Daniel Nowak, Yasunobu Nagata, Ryo Yamamoto, Yusuke Sato, Aiko Sato-Otsubo, Ayana Kon, Masao Nagasaki, George Chalkidis, Yutaka Suzuki, Makoto Otsu, Naoshi Obara, Mamiko Sakata-Yanagimoto, Ken Ishiyama, Hiraku Mori, Florian Nolte, Wolf-Karsten Hofmann, Shuichi Miyawaki, Sumio Sugano, Claudia Haferlach, H. Phillip Koeffler, Lee-Yung Shih, Torsten Haferlach, Shigeru Chiba, Hiromitsu Nakauchi, Satoru Miyano, Seishi Ogawa
Journal: Blood (2011)
P3.02c-075 Could Blood Levels of Lymphocytes and Eosinophils Help Us to Identify the Efficacy or Toxicity of Immunotherapy?
Authors: Eugenia Olmedo, Jacobo Muñoz Del Toro, Luis Gorospe, Josefa Perez Templado, Ana Gomez, Pablo Reguera, María Gión, Ainhoa Madariaga, Olga Martínez, Javier Molina, María Villamayor, Victor Albarrán, Arantzazu Barquin, Cristina Saavedra, Ainara Soria, Teresa Alonso, Pablo Gajate, Enrique Grande, Pilar Garrido
Journal: Journal of Thoracic Oncology (2017)
Surgical Treatment of Nonlesional Neocortical Epilepsy
Authors: Dong Wook Kim, Sang Kun Lee, Hye-Jin Moon, Ki-Young Jung, Kon Chu, Chun-Ki Chung
Journal: JAMA Neurology (2017)

The proportion of surgery for nonlesional neocortical epilepsy has recently increased, with a decrease in surgery for mesial temporal lobe epilepsy. However, there are only a few studies regarding the long-term surgical outcome and the potential prognostic factors for patients with nonlesional neocortical epilepsy.To evaluate the long-term surgical outcome and to identify possible prognostic factors in patients with nonlesional neocortical epilepsy.In a surgical cohort from September 1995 to December 2005 at the Seoul National University Hospital, we included 109 consecutive patients without lesions identifiable by magnetic resonance imaging who underwent focal surgical resection for drug-resistant neocortical epilepsy. Follow-up information for at least 10 years was available for all but 1 patient.Univariate and standard multiple logistic regression analyses were performed to identify the predictors of surgical outcomes, and a generalized estimation equation model was used for the longitudinal multiple logistic regression analysis of up to 21 years of follow-up.The patients consisted of 64 men and 45 women with ages at surgery ranging from 7 to 56 years (mean [SD], 27.1 [7.8] years). At 1 year after surgery, 59 of 109 patients (54.1%) achieved seizure freedom, and 64 of 108 patients (59.3%) achieved seizure freedom at the last follow-up. Only 11 of 108 patients (10.2%) experienced definite changes in postoperative seizure status. Localizing patterns in functional neuroimaging (strongest odds ratio [OR], 0.30 [95% CI, 0.14-0.66] for fluorodeoxyglucose-positron emission tomography; 0.37 [95% CI, 0.15-0.87] for ictal single-photon emission computed tomography), concordant results in presurgical diagnostic evaluations (OR, 3.15 [95% CI, 1.42-7.02]), the presence of aura (OR, 3.49 [95% CI, 1.54-7.92]), and complete resection of areas of ictal onset with frequent interictal spikes during the intracranial electroencephalographic study (OR, 0.37 [95% CI, 0.16-0.85]) were favorable surgical outcome predictors.Our study showed that nearly 60% of patients with nonlesional neocortical epilepsy achieved freedom from long-term seizure, and that changes in postoperative seizure status were rarely observed. Several predictors of favorable surgical outcomes were identified, which can help select optimal candidates for surgical treatment among patients with nonlesional neocortical epilepsy.
P2.04-016 Is FDG-PET Useful for Distinguishing between Thymic Epithelial Tumors and Malignant Lymphoma?
Authors: Hiroyuki Sakamaki, Takashi Ohtsuka, Yota Suzuki, Shouji Kuriyama, Kenichi Hamada, Toshiyuki Shima, Masaya Yotsukura, Kyohei Masai, Tomonari Kinoshita, Kaoru Kaseda, Ikuo Kamiyama, Yuichiro Hayashi, Hisao Asamura
Journal: Journal of Thoracic Oncology (2017)
P3.02b-127 NSCLC Patients Harboring HER2 Mutation: Clinical Characteristics and Management in Real World Setting. EXPLORE GFPC 02-14
Authors: Jean Bernard Auliac, Pascal Do, Sophie Bayle, Helene Doubre, Florent Vinas, Jacques Letreut, Gislaine Fraboulet, Lionel Falchero, Pascal Thomas, Christos Chouaid
Journal: Journal of Thoracic Oncology (2017)
Thrombopoietin Protects Against Cardiotoxicity Induced by Doxorubicin.
Authors: Rita Y.T. Sung, Wei Zhe Huang, Mo Yang, Nga Hin Pong, Shuk Man Lee, Wood Yee Chan, Yeuk Oi Wong, Da Wei Xiao, Man Yin To, Karen K.H. Li
Journal: Blood (2004)
P3.02c-061 Neutrophil/Lymphocyte Ratio Predicts the Efficacy of Anti-PD-1 Antibody in Patients with Advanced Lung Cancer
Authors: Koung Jin Suh, Se Hyun Kim, Yu Jung Kim, Miso Kim, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Jong Seok Lee
Journal: Journal of Thoracic Oncology (2017)
Comparison of Conventional Versus Lineage-Specific Chimerism Analysis for Detection of Minimal Residual Disease or Relapse in Myeloid Malignancies after Myeloablative Allogeneic Hematopoietic Cell Transplantation with Respect to Clinical Follow-Up.
Authors: Robert Zeiser, Alexandros Spyridonidis, Ralph Waesch, Gabriele Ihorst, Carsten Grullich, Bertz Hartmut, Finke Jurgen
Journal: Blood (2004)
P2.04-036 Giant Primary Dedifferentiated Liposarcoma of the Anterior Mediastinum: An Extremely Rare Occurrence
Authors: Luigi Ventura, Letizia Gnetti, Cesare Braggio, Valeria Balestra, Paolo Carbognani, Enrico Maria Silini, Michele Rusca, Luca Ampollini
Journal: Journal of Thoracic Oncology (2017)
P2.03b-045 Assessment of microRNAs in FFPE Tissue for Prediction of the Effect of Palliative Chemotherapy for Squamous Cell Carcinoma of the Lung
Authors: Martin Svaton, Vlastimil Kulda, Petr Mukensnabl, Ondrej Topolcan, Milos Pesek, Martin Pesta
Journal: Journal of Thoracic Oncology (2017)
Updated safety results from EXIST-2: Everolimus therapy for angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (sLAM).
Authors: John Bissler, Christopher Kingswood, B. A. Zonnenberg, Michael Frost, Elena Belousova, Elzbieta Radzikowska, Matthias Sauter, Norio Nonomura, Susan Brakemeier, Petrus de Vries, Judith Klimovsky, Gaurav D. Shah, Sara Miao, Jeremie Lincy, Klemens Budde
Journal: Journal of Clinical Oncology (2012)

4632 Background: EXIST-2 (NCT00790400) is a randomized, double-blind, placebo-controlled, phase 3 trial assessing the efficacy and safety of everolimus, an oral mTOR inhibitor, for treating AML in patients with TSC or sLAM. We have previously reported that everolimus resulted in a significantly higher AML response rate vs placebo (41.8% vs 0%; 95% CI: 23.5–58.4; p&lt;0.0001) with a consistent safety profile (Bissler et al. J Am Soc Nephrol. 22, 2011, Abstract LB-PO3159). Here we present a 90-day safety update. Methods: 118 eligible patients were randomized 2:1 to receive everolimus 10 mg daily (n=79) or placebo (n=39). The primary efficacy endpoint was AML response rate (proportion of patients with best overall AML response status of “response”). Original cut-off date for data analysis was 30 Jun 2011. An updated analysis of the safety data for the safety set (all patients receiving ≥1 dose of double-blind study drug with a valid post-baseline assessment) to 14 Oct 2011 are presented here. Results: As of 14 Oct 2011, median treatment duration was 48.1 and 45.0 weeks for everolimus and placebo arms, respectively. Discontinuations in the double-blind period were the same in the everolimus arm as the initial analysis, but had increased by 4 patients in the placebo arm since initial analysis (3 due to disease progression, 1 withdrew consent). The majority of adverse events (AEs) continued to be grade 1 or 2; the incidence of serious AEs was slightly higher than initially reported, particularly in the placebo arm (everolimus 20.3%, placebo 23.1%). AE incidence leading to discontinuation was the same as initially reported (everolimus 3.8%, placebo 10.3%). In the updated data, 3 additional everolimus patients required dose interruption or reduction due to AEs; dose reduction/interruption remained more common in the everolimus arm (51.9% vs. 20.5%). Conclusions: Overall, the 90-day updated safety data analysis from the EXIST-2 trial has not revealed any additional safety concerns. No other patients receiving everolimus withdrew for any reason, whereas 3 more patients receiving placebo withdrew due to disease progression.
Circulating adiponectin levels in relation to carotid atherosclerotic plaque presence, ischemic stroke risk, and mortality: A systematic review and meta-analyses
Authors: Jessica Gorgui, Karina Gasbarrino, Marios K. Georgakis, Maria A. Karalexi, Bénédicte Nauche, Eleni Th. Petridou, Stella S. Daskalopoulou
Journal: Metabolism (2017)
P2.03a-002 Patterns of Chemotherapy Use and Overall Survival (OS) of Patients with Stage IV Squamous Lung Cancer (SCC)
Authors: Saiama Waqar, Pamela Samson, Feng Gao, Lingling Du, Siddhartha Devarakonda, Cliff Robinson, Varun Puri, Ramaswamy Govindan, Daniel Morgensztern
Journal: Journal of Thoracic Oncology (2017)
Mito-FLAG with Ara-C as Bolus Vs. Continuous Infusion in Recurrent AML – Results of a Prospective Randomized Intergroup Study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemias (SAL)
Authors: Mathias Hanel, Kai Friedrichsen, Frank Kroschinsky, Wolfram Poenisch, Kerstin Schaefer-Eckart, Walter Aulitzky, Norma Peter, Sascha Neugebauer, Regina Herbst, Annette Hanel, Martin Wilhelm, Dietger Niederwieser, Gerhard Ehninger, Friedrich Fiedler
Journal: Blood (2008)
Evolution of Anti-ADAMTS13 Antibodies in a Refractory Case of Thrombotic Thrombocytopenic Purpura with Fatal Outcome
Authors: Barbara Plaimauer, Paul Knoebl, Susanna Skalicky, Silvia Ferrari, Katalin Varadi, Vera Kolovratova, Peter L. Turecek, Manfred Rieger, Friedrich Scheiflinger
Journal: Blood (2008)
PUB112 Comparison of Two Atlases to Delineate Organ at Risks Contouring in Lung Cancer Radiation Therapy
Authors: Maria Taraborrelli, Marianna Nuzzo, Marianna Trignani, Annamaria Vinciguerra, Antonietta Augurio, Francesca Perrotti, Giusy Caponigro, Mariarosa Di Biase, Domenico Genovesi
Journal: Journal of Thoracic Oncology (2017)
Abstract B07: Differential roles for AKT isoforms in BRAF mutant melanoma
Authors: Siobhan K. McRee, Jodie R. Pietruska, Elisabeth Dignan, Philip W. Hinds
Journal: Clinical Cancer Research (2017)

Abstract Despite recent advances, melanoma remains the deadliest form of skin cancer, and new therapeutic strategies are urgently needed. The MAP kinase (MAPK) and PI3K/AKT pathways are central to both disease progression and chemoresistance in melanoma, with dual targeting approaches yielding promising results that would benefit from increased target specificity and selectivity. The AKT family of serine/threonine kinases comprises three highly homologous and functionally distinct isoforms (AKT1, AKT2, and AKT3) that play unique roles in melanoma but have not yet been leveraged for isoform-specific targeting. Our lab has engineered a unique mouse model of melanoma, in which mutant BRAFV600E is constitutively targeted to mouse melanocytes, resulting in spontaneous malignant disease upon additional loss of tumor suppressor genes, and faithfully recapitulates the human disease. We have identified differential and dynamic activation of AKT isoforms in our mouse melanoma model, which supports the hypothesis that AKT isoforms may play both non-redundant and compensatory roles in melanoma progression. To systematically address this question, we have genetically ablated each AKT isoform individually in melanoma-prone mice in order to elucidate the individual and unique contribution of each isoform to melanoma progression. In parallel, we performed in vitro studies using shRNA mediated conditional knockdown of AKTs in a wide variety of human melanoma cell lines. Our results support an isoform-specific role for AKT1 in promoting melanoma cell proliferation, while AKT2 stimulates cell migration. Further studies utilizing the precision genome editing technology CRISPR/Cas9 allows us to interrogate the effects of AKT isoform specific knockout (KO) on in vivo tumor formation. This work moves toward establishing the contribution of AKT isoforms to tumor progression in melanoma, using both human melanoma cell lines and mouse models, to advance our understanding of the role of AKT in melanomagenesis. With AKT inhibitors in clinical trials for melanoma, our findings could yield novel therapeutic strategies and increase the efficiency of existing therapies to improve treatment options and outcome for this devastating disease. Citation Format: Siobhan K. McRee, Jodie R. Pietruska, Elisabeth Dignan, Philip W. Hinds. Differential roles for AKT isoforms in BRAF mutant melanoma. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(1_Suppl):Abstract nr B07.
ZAP-70 Expression in Human B cells: Analysis of Normal Cells and Acute Lymphoblastic Leukemia (ALL) Cells with Pro/Pre B Phenotype.
Authors: Marta Crespo, Neus Villamor, Eva Gine, Dolors Colomer, Teresa Marafioti, Elies Campo, Emili Montserrat, Francesc Bosch
Journal: Blood (2004)
Different Pattern of Expression of CD52, CD20 and CXCR-4 in Peripheral Blood, Bone Marrow and Lymph Nodes in B-Cell Chronic Lymphocytic Leukemia (B-CLL),
Authors: Ozren Jaksic, Branimir Gizdic, Tajana Stoos Veic, Vlatka Pandzic Jaksic, Rajko Kusec, Vlatko Pejsa, Branimir Jaksic
Journal: Blood (2011)
Transcriptional Down-Regulation of the Wnt Antagonist SFRP1 Is Associated to Promoter Hypermethylation as Detected by Pyrosequencing in Hematopoietic Cells of Patients with Different Risk-Types of MDS, ALL and AML.
Authors: Jana Reins, Maximilian Mossner, Uwe Platzbecker, Eckhard Thiel, Wolf-Karsten Hofmann
Journal: Blood (2009)
Comparison of Matched/Mismatched Unrelated Donor Stem Cell Transplantation to Autologous Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
Authors: Francesco Saraceni, Myriam Labopin, Norbert Claude Gorin, Didier Blaise, Reza Tabrizi, Liisa Volin, Jan Cornelissen, Jean-Yves Cahn, Patrice Chevallier, Charles Craddock, Depei Wu, Anne Huynh, William Arcese, Mohamad Mohty, Arnon Nagler
Journal: Blood (2015)
P3.02b-005 Phase Ib Trial of Afatinib and BI 836845 in Advanced NSCLC: Dose Escalation and Safety Results
Authors: Keunchil Park, Byoung Chul Cho, Ki Hyeong Lee, Wu-Chou Su, Sang-We Kim, Chia-Chi Lin, Dennis Chin-Lun Huang, Helen Hayoun Jung, Yuan Geng, Daniel Shao Weng Tan
Journal: Journal of Thoracic Oncology (2017)
Allogeneic Stem Cell Transplantation (allo-SCT) for Isolated and Leukemic Myeloid Sarcoma (GS): a Survey on Behalf of the Acute Leukemia Working Party (ALWP) of EBMT.
Authors: Patrice Chevallier, Myriam Labopin, Jan J. Cornelissen, Gérard Socié, Per T. Ljungman, Bruno Lioure, Herve Tilly, Alois Gratwohl, Noel Milpied, Ibrahim Yakoub-Agha, Liisa Volin, Jean-Paul Vernant, Jacques-Olivier Bay, Mauricette Michallet, Agnès Buzyn, Benedicte Samey, Mohamad Mohty, Vanderson Rocha
Journal: Blood (2010)
Imatinib Interim Therapy Has Favorable Impact on the Outcome of Patients with Ph+ ALL Treated with Allogeneic SCT.
Authors: Lee Seok, Yoo-Jin Kim, Chang-Ki Min, Hee-Je Kim, Ki-Sung Eom, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min, Chun-Choo Kim
Journal: Blood (2004)
P1.05-035 SABR for Medically Inoperable Early Stage NSCLC at the Beatson West of Scotland Cancer Centre: Outcomes and Toxicity
Authors: Stephen Mckay, Karen Moore, Jennifer Macphee, Jonathan Hicks, Graeme Lumsden, Vivienne Maclaren, Andy Aitken, David Stobo, Gordon Cowell, Philip Mcloone, Stephen Harrow
Journal: Journal of Thoracic Oncology (2017)
P1.03-030 FDG-PET/CT Might Be a Predictor for Residual Disease in Advanced NSCLC after Chemoradiotherapy
Authors: Toru Sawada, Kazuya Kondo, Mitsuhiro Tsuboi, Naoya Kawakita, Koichiro Kajiura, Hiroaki Toba, Yukikiyo Kawakami, Mitsuteru Yoshida, Hiromitsu Takizawa, Akira Tangoku
Journal: Journal of Thoracic Oncology (2017)
Thirty Percent Long Term Survival In Children with Acute Leukemia and Complications Requiring Mechanical Ventilation
Authors: Daniel Steinbach, Bernhard Wilhelm, Hans-Rudolf Kiermaier, Ursula Creutzig, Martin Schrappe, Martin Zimmermann, Klaus-Michael Debatin, Bernd Gruhn, Arend von Stackelberg, Heribert Jürgens, Brigitte Strahm, Dirk Reinhardt, Anja Möricke
Journal: Blood (2010)